The Knight ADRC has supported many investigators at Washington University and at other institutions over the years. We wish to avoid the situation where two investigators study the same research question to avoid duplication of effort and potential conflict. To determine if your topic has already been studied with our resources, please search our database. If you find that your topic or a related topic has been submitted, you may wish to contact the investigator to inquire about their findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID number (e.g. T1004), the full request has been submitted and is either approved, disapproved or in process. If an entry has no ID number, then it represents a submission that has not yet been reviewed. Search terms are applied across an entire requests application including variables not displayed below. A more specific, detailed search may yield better results depending upon your needs.
Search Terms:
Investigator: Xinyuan Bi
Project Title: Multi-modal diagnosis of Alzheimer’s disease
Date: May 28, 2026 at 2:25 am
Request ID:
Aim 1: Screening the biomarkers and identify the potential causal link among biomarkers
Aim 2: Establish a diagnostic model for Alzheimer’s disease using deep learning
Aim 3: Establish a multi-modal assay for Alzheimer’s disease-related biomarkers
Aim 4:
Investigator: Aneesh Asokan
Project Title: Validation of Plasma Biomarkers for Aging and Neurodegeneration in Asian Indian Populations
Date: May 26, 2026 at 5:23 am
Request ID:
Aim 1: Identify plasma protein biomarkers associated with aging and neurodegenerative phenotypes in Asian Indian populations the NULISAseq platform.
Aim 2: Replicate and validate biomarker candidates in European/North American cohorts (including ADRC) across South Asian cohorts via cross-cohort proteomics comparison.
Aim 3: Perform pathway enrichment analyses to characterize biological mechanisms underlying differential biomarker expression across populations.
Aim 4: To characterize the population-level distribution of established neurodegenerative biomarkers including p-Tau217, NfL, Aβ42, GFAP, and APOE4, in an Indian cohort and benchmark these profiles against globally reported reference cohorts.
Investigator: Shipeng Xiong
Project Title: A Machine Learning Workflow for Screening Alzheimer’s Disease Based on Plasma p-tau217/Aβ1–42
Date: May 21, 2026 at 5:52 pm
Request ID:
Aim 1: To reduce the interval of indeterminate results, by developing a workflow for AD risk stratification of participants with cognitive impairment.
Aim 2:
Aim 3:
Aim 4:
Investigator: Annie Lee
Project Title: Dynamic Multi-Omics Modeling of Heterogeneous Clinico-Neuropathological Progression in Alzheimer’s Disease
Date: May 20, 2026 at 9:46 pm
Request ID:
Aim 1: Identify dynamic preclinical clinico-neuropathological subgroups that define heterogeneous trajectories preceding dementia onset. We request Clinical data (e.g., longitudinal cognition, diagnosis), Fluid Biomarker data (e.g., longitudinal CSF and blood), and available multi-omics data.
Aim 2: Identify post-diagnosis progression subgroups associated with heterogeneous clinical progression and survival. We request Clinical data (e.g., longitudinal functional outcomes), Fluid Biomarker data, and Genetics data (e.g., available multi-omics data).
Aim 3: Identify molecular mechanisms underlying heterogeneous disease trajectories across progression subgroups.
Aim 4:
Investigator: Marufjon Salokhiddinov
Project Title: Multimodal Neuroimaging and Biomarker-Based Prediction of Early Alzheimer’s Disease Progression Using Knight ADRC Longitudinal Data
Date: May 19, 2026 at 11:52 pm
Request ID:
Aim 1: To quantify the relationship between structural MRI volumetric markers and Alzheimer’s disease biomarker status. This aim will evaluate whether regional brain volume measures are associated with amyloid positiv
Aim 2: To determine whether baseline MRI volumetric markers predict longitudinal cognitive decline and clinical progression.
Aim 3: To develop and validate a multimodal prediction model combining MRI, clinical, cognitive, and biomarker data for early Alzheimer’s disease risk stratification.
Aim 4: To evaluate whether MRI-based volumetric signatures differ across biomarker-defined Alzheimer’s disease stages and can detect preclinical neurodegeneration before overt cognitive impairment.
Investigator: Marta Porniece
Project Title: Exploration of CSF and plasma proteomics
Date: May 19, 2026 at 8:59 am
Request ID:
Aim 1: Primary aim is to conduct a targeted reanalysis of the CSF SomaLink proteomic profiles to investigate how biological factors, specifically age, sex, and BMI, influence the protein-balance signatures identified in the original study and correlate these to plasma proteome.
Aim 2: Analyzing the individual proteomic profiles within the blood (plasma) and correlate these to age, sex, and BMI,
Aim 3: Analyzing the individual proteomic profiles within the CSF and correlate these to age, sex, and BMI,
Aim 4:
Investigator: Yue Huang
Project Title: CSF MMP10 as a renal-function–modified marker of cognitive vulnerability in aging and Alzheimer’s disease
Date: May 19, 2026 at 7:44 am
Request ID:
Aim 1: Validate whether CSF MMP10 is associated with baseline cognitive impairment and dementia severity in Knight ADRC participants
Aim 2: Test whether CSF MMP10 predicts longitudinal cognitive decline across memory, global cognition, and CDR-based outcomes.
Aim 3: Examine whether CSF MMP10 is associated with MRI markers of vascular brain injury, including WMH burden and brain atrophy.
Aim 4: Explore whether renal dysfunction or kidney disease history modifies the association of CSF MMP10 with cognitive decline and MRI injury.
Investigator: Takahisa Kanekiyo, M.D., Ph.D
Project Title: Immune activation markers in age-related cognitive decline and Alzheimer’s disease
Date: May 14, 2026 at 9:02 am
Request ID:
Aim 1: alidate CSF biomarker profiles associated with conversion from MCI to dementia, with a focus on inflammatory and AD-related markers that may improve prediction of disease progression beyond established CSF biomarkers.
Aim 2: Validate plasma biomarker signatures associated with progression from cognitively unimpaired status to mild cognitive impairment, focusing on inflammatory and Alzheimer’s disease-related biomarkers that may predict incident MCI among cognitively unimpaired individuals.
Aim 3:
Aim 4:
Investigator: FU XIAOZHOU
Project Title: Construction of a Predictive Model for the Conversion from Cognitive Impairment to Alzheimer’s Disease Based on Multimodal Feature Fusion
Date: May 12, 2026 at 3:42 am
Request ID:
Aim 1: Biomarker Discovery
Aim 2:
Aim 3:
Aim 4:
Investigator: Elham Ghanbarian
Project Title: Inflammation and Non-Amyloid Neurodegeneration in Aging and Alzheimer’s Disease
Date: May 8, 2026 at 11:54 am
Request ID: D2629
Aim 1: To investigate the contribution of non-amyloid neurodegenerative processes to cognitive decline and medial temporal lobe degeneration in aging
Aim 2: To investigate the contribution of systemic inflammation to cognitive decline and medial temporal lobe degeneration in aging
Aim 3: To assess the potential of non-amyloid degeneration processes and systemic inflammation to improve differentiation between Alzheimer’s disease and related pathologies such as LATE
Aim 4: